New Zealand prepares to open its doors to xenotransplantation trials
This article was originally published in Clinica
New Zealand cell therapy firm Living Cell Technologies (Auckland) has received conditional government approval for clinical trials to go ahead on its DiabeCell Type 1 diabetes treatment. The company is hopeful that trials of its technology, which involves the transplantation into humans of living cells from pigs – “natural neo-natal porcine islets encapsulated in an alginate gel” – will soon be approved in the US too. “We are currently in talks with the FDA, and if all goes well we might get approval by mid-2009,” medical director Bob Elliott told Clinica.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.